Park SW, et al. - Using the National Health Insurance claims data for the entire Korean population, researchers determined the risk factors of incident immune-mediated diseases and the impact of comorbid immune-mediated diseases on outcomes in inflammatory bowel disease (IBD). From 2012 to 2013, 35,581 IBD patients without immune-mediated diseases and 595 IBD patients with immune-mediated diseases were identified and follow-up until 2016. Vasculitis, psoriatic arthropathy, systemic lupus erythematous, vasculitis, rheumatoid arthritis and multiple sclerosis were the immune-mediated diseases with an increased risk in IBD. As compared to non-IBD population, the incidence of immune-mediated diseases in IBD patients was higher. Adult age and frequent hospitalisation were the risk factors for comorbid immune-mediated disease. In contrast, a history of 5-aminosalicylic acid (5-ASA) use had a protective effect for developing the immune-mediated disease. The presence of other immune-mediated diseases in IBD patients was linked to poor outcomes like new anti-TNF-α therapy and developing acute flare.